p32 inhibitor M36 (M36) is a small molecule inhibitor of p32 mitochondrial protein that can directly bind to p32 and inhibit the binding of p32 to LyP-1.

Physicochemical Properties

Molecular Formula	C23H28N8O2
Molecular Weight	448.520823478699
Exact Mass	448.233
CAS #	802555-85-7
PubChem CID	416381
Appearance	White to off-white solid powder
LogP	-0.1
Hydrogen Bond Donor Count	6
Hydrogen Bond Acceptor Count	4
Rotatable Bond Count	8
Heavy Atom Count	33
Complexity	680
Defined Atom Stereocenter Count	0
SMILES	O=C(NCCCNC(NC1C=C(C2NCCN=2)C=CC=1)=O)NC1C=C(C2NCCN=2)C=CC=1
InChi Key	HHFOXYBNULCICF-UHFFFAOYSA-N
InChi Code	InChI=1S/C23H28N8O2/c32-22(30-18-6-1-4-16(14-18)20-24-10-11-25-20)28-8-3-9-29-23(33)31-19-7-2-5-17(15-19)21-26-12-13-27-21/h1-2,4-7,14-15H,3,8-13H2,(H,24,25)(H,26,27)(H2,28,30,32)(H2,29,31,33)
Chemical Name	1-[3-(4,5-dihydro-1H-imidazol-2-yl)phenyl]-3-[3-[[3-(4,5-dihydro-1H-imidazol-2-yl)phenyl]carbamoylamino]propyl]urea
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vitro	M36, a p32 inhibitor, has an IC50 of 77.9 μM in full medium, which is more efficient at inhibiting the growth of SF188 glioma cells when glucose levels are low (IC50 of 7.3 μM) [1]. M36, a p32 inhibitor, is specific to cells that overexpress p32 [1]. With an IC50 of 2.8 μM, p32 Inhibitor M36 is another strong neurosphere inhibitor developed from patients [1].
References	[1]. A novel small molecule inhibitor of p32 mitochondrial protein overexpressed in glioma. J Transl Med. 2017 Oct 18;15(1):210.

Solubility Data

Solubility (In Vitro)

DMSO : ~5 mg/mL (~11.15 mM)

Solubility (In Vivo)

Solubility in Formulation 1: 1.82 mg/mL (4.06 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 18.2 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.82 mg/mL (4.06 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 18.2 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	2.2296 mL	11.1478 mL	22.2955 mL
	5 mM	0.4459 mL	2.2296 mL	4.4591 mL
	10 mM	0.2230 mL	1.1148 mL	2.2296 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.